|
gptkbp:instanceOf
|
gptkb:clinical_trial
|
|
gptkbp:clinicalTrialPhase
|
NCT00262600
|
|
gptkbp:conditionStudied
|
gptkb:atrial_fibrillation
|
|
gptkbp:foundIn
|
dabigatran 150 mg was non-inferior to warfarin for stroke prevention
dabigatran 110 mg had similar efficacy to warfarin with lower bleeding risk
dabigatran 150 mg had lower rates of intracranial hemorrhage than warfarin
|
|
gptkbp:fullName
|
Randomized Evaluation of Long-Term Anticoagulation Therapy
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
RE-LY trial
|
|
gptkbp:location
|
multinational
|
|
gptkbp:participants
|
18113
|
|
gptkbp:principalInvestigator
|
gptkb:Salim_Yusuf
|
|
gptkbp:publicationDate
|
2009-09-17
|
|
gptkbp:publicationYear
|
2009
|
|
gptkbp:publishedIn
|
gptkb:New_England_Journal_of_Medicine
|
|
gptkbp:result
|
stroke prevention
systemic embolism prevention
|
|
gptkbp:sponsor
|
gptkb:Boehringer_Ingelheim
|
|
gptkbp:startYear
|
2005
|
|
gptkbp:studiedDrug
|
gptkb:warfarin
gptkb:dabigatran
|
|
gptkbp:studyType
|
gptkb:clinical_trial
open-label
blinded endpoint evaluation
|
|
gptkbp:bfsParent
|
gptkb:Clinical_Trial_Service_Unit
|
|
gptkbp:bfsLayer
|
7
|